Sophia Genetics (SOPH) announced a new milestone in the adoption of its cancer testing applications MSK-Access powered with Sophia DDM and MSK-Impact powered with Sophia DDM. Thirty-seven institutions have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.